Skip to content
OpenCapital
Earnings
Screener
Charts
Portfolio
Pricing
Connect your AI
Get started
Toggle navigation menu
Stocks
Supernus Pharmaceuticals
Business Segments
Products & Services
Revenue, remaining performance obligation, variable consideration amount
Revenue, remaining performance obligation, variable consideration amount
Supernus Pharmaceuticals
·
Products & Services
·
1 segment
Breakdown
Segments
License
View metric
Quarterly
Annual
TTM
Segment
Q3 '25
Q4 '25
Q1 '26
License
$470M
$470M
$470M
Total
$470M
$470M
$470M
